LinkedIn Outreach for Series A Healthtech Decision Makers (2026)

In 2026, the fastest way to run a LinkedIn outreach campaign targeting Series A healthtech decision makers is through Origami, which has a built-in LinkedIn sequencer. You describe your ideal customer, and Origami’s AI builds a verified prospect list. Then, you create a sequence and send connection requests and follow-ups directly from the same platform — no CSV exports, no third-party tools.

This guide assumes you’ve already built a list of healthtech leaders — founders, heads of product, VPs of engineering, clinical leads — using Origami’s search. If you haven’t, first read how to build a list of Series A Healthtech Decision Makers. Here, I’ll walk you through refining that list, writing a 3-touch LinkedIn sequence you can steal, and launching it inside Origami. I’ll also share the response rates I’ve seen when running this exact playbook.

Step 1: Build the List in Origami

Even if you already pulled a list, let’s ground ourselves in the prompt you’d use. Inside Origami, you describe your ideal customer in plain English. The AI agent searches the live web, chains data sources, and returns enriched contacts with names, verified emails, direct phone numbers, job titles, company information, and sometimes even technology-stack clues. For Series A healthtech decision makers, a solid prompt looks like:

“Find decision makers at US-based healthtech startups that raised a Series A in the last 12 months. I need founders, CTOs, heads of product, VPs of engineering, and clinical or regulatory leads. Company size 20–150 employees. Exclude anyone at pre-seed or growth-stage companies.”

Origami returns a clean list you can sort by role, company, location, or funding round. If you’re on the free plan, you get 1,000 credits (no credit card needed) — plenty to test this exact campaign. Paid plans start at $29/month and give you enough credits to run ongoing, multi-touch outreach.

From here, you have a list of 50, 150, or 500 names. The next step is where most outreach breaks down: blasting everyone the same message. Let’s avoid that.

Step 2: Refine and Qualify

A list from Origami is already pre-qualified — it only includes contacts matching your plain-English prompt. But you still need to segment and remove misfits before you write a single connection note.

For a Series A healthtech campaign, here’s what “qualified” looks like and how to segment the list for maximum relevance.

Company-level filters

Inside Origami’s list view, you can filter by company size, location, and funding stage. Even better: tag contacts with custom labels. I recommend creating tags like:

• Regulated devices — companies with FDA/CE mark ambitions
• SaaS healthtech — digital health platforms, RPM, telemedicine
• Biotech overlap — those at the intersection of software and drug discovery

Why? Because a CTO at a D2C telehealth app doesn’t share the same pain points as a CTO building an FDA-cleared AI diagnostic tool. You’ll tailor your messaging later based on these segments.

Remove any contact where:

• The company didn’t actually raise a Series A (Origami is accurate, but occasionally a legacy round gets tagged incorrectly)
• The person’s role is purely administrative or not involved in product/engineering/strategy decisions
• You notice obvious title inflation (a “VP of Growth” at a 20-person startup rarely has budget authority)

Persona-level segmentation

Break the remaining list into three core personas:

1. Founder / CEO / COO — worried about runway, go-to-market velocity, and hitting clinical milestones before the next raise
2. CTO / VP Engineering / Head of Product — preoccupied with building compliant, scalable infrastructure, hiring technical talent, and integrating with legacy hospital IT systems
3. Clinical / Regulatory / Quality leads — tasked with managing 510(k) submissions, ISO 13485, IRB protocols, and real-world evidence collection

Write each of these three groups its own set of conversation templates — don’t try to write one sequence for everyone. The messaging that resonates with a founder won’t land with a regulatory manager, and vice versa. Below I’ve written a full 3-touch sequence tailored to the founder/CEO persona, which is usually the highest-value starting point.

You can adapt the language for the other two personas using the same structure; I’ll note where to make those swaps.

Step 3: Create the LinkedIn Sequence

Here’s where Origami’s built-in sequencer changes the game. You have two ways to build your outreach flow:

1. Paste your own templates. Write a 3-touch sequence yourself, paste the messages into Origami, set the delays between touches (Day 1 connection request, Day 3 follow-up, Day 7 final note, or whatever cadence you prefer), and hit Launch.
2. Let the AI agent write it. Ask Origami’s agent to generate a personalized 3-day LinkedIn sequence for all leads automatically. The agent reads each contact’s enriched profile — title, company description, technologies used, recent news — and writes messages that feel individually written for that person. You can review and tweak before sending.

Most experienced operators I know start with option 1, because you want to dial in the copy yourself. Once you’ve proven the messaging works, you can switch to option 2 to scale across multiple segments. Below, I’m giving you the exact copy for option 1.

3-Touch LinkedIn Sequence for Series A Healthtech Founders/CEOs

These messages are designed to be sent as connection requests with a note, then direct messages once they accept. No InMail credits wasted. Keep the tone direct and human — founders see robotic pitches constantly. Each message is 50–100 words, and I’ve written them so you can copy, paste, and lightly customize.

Touch 1: Connection request note (Day 1)

Character limit is 300, so keep it tight.

“Hi , saw you’re leading — the post-Series A push toward [clinical validation / provider adoption] is a familiar mountain. I help healthtech founders shorten the time from raise to first 10 enterprise pilots without burning engineering resources on integrations. Happy to connect here.”

Why it works: It names a specific transition moment (post-Series A push), acknowledges the real work (enterprise pilots, integrations), and offers a concrete outcome without pitching anything.

If you’re messaging a CTO or VP Engineering instead of a founder, swap the angle: “...post-Series A push toward scalable, audit-ready infrastructure is a familiar mountain. I help healthtech CTOs build FDA-compliant platforms without ballooning cloud costs.” For regulatory leads: “...post-Series A push toward 510(k) clearance is a familiar mountain. I help regulatory leads compress submission timelines by aligning software architecture with predicate-device data models.”

Touch 2: Follow-up message (Day 3 after connection accepted)

Now that you’re connected, send a direct message. No need for a subject line on LinkedIn DM, but you can bold the opening line for scannability.

Hey , thanks for connecting.
I’ve been following ’s work on [specific feature/announcement — if Origami’s enrichment pulled recent news, drop it here; otherwise use “your product’s real-world data integration”].
A few healthtech teams we work with hit a wall after Series A: they need clinical evidence to sell, but building the data infrastructure alone steals 4–6 months. We built a framework that maps directly to 510(k) or MDD timelines and typically cuts that to weeks.
If you’re thinking about how to derisk the next six months, I’m happy to share a case study. No pitch.

~85 words. It’s a soft share that focuses on derisking a known bottleneck.

For CTO/Eng: swap “clinical evidence” to “audit-ready architecture” and “510(k) or MDD timelines” to “SOC 2 / HITRUST timelines.” For regulatory: keep clinical evidence but emphasize “pre-submission meetings” and “FDA reviewer feedback loops.”

Touch 3: Final message (Day 7)

If you still haven’t heard back, send one last message. The goal is to leave a door open without guilt-tripping anyone.

Last one, — I promise.
If 2026 is the year you prove clinical or commercial traction, you’re probably deep in sequencing experiments, partnership conversations, and hiring. When the time comes to look at infrastructure that shortens the evidence-generation cycle, a few founders have found this useful: [insert link to a no-opt-in resource — a 1-pager or ungated case study].
No reply needed. If timing shifts, I’m here.

~85 words. The link is optional but powerful when it delivers genuine value. I’ve used an ungated “playbook” that walks through 3 common compliance architecture patterns, and it consistently generates replies from founders who were silent for weeks.

For CTOs, make the link a technical architecture reference; for regulatory leads, a checklist mapping software V&V to 510(k) requirements.

These three touches form a complete sequence. You can paste them into Origami’s sequencer now.

Step 4: Send the Sequence Directly from Origami

Once you’ve written (or approved) your sequence, you launch it inside Origami — no exporting CSVs, no syncing with a separate outreach tool. The built-in LinkedIn sequencer handles everything: connection requests go out with your note on Day 1, follow-ups fire automatically after the delay you set (e.g., 3 days after acceptance for touch 2, 4 more days for touch 3).

What you see in the dashboard

Origami’s sequence dashboard shows opens, clicks, and replies — right next to the same enriched prospect profiles you used when building the list. While looking at a contact’s activity, you can still see their full title, company details, technologies used, and any notes you added during refinement. That context matters: you know exactly why you reached out and what you wanted to learn, so when a reply lands, you’re ready to have a real conversation.

Automatic un-enrollment

If someone replies — even with a simple “not interested” — Origami pulls them out of the sequence. You never accidentally send a “just following up” message to a person who already booked a meeting or declined. This single feature saves your reputation and a lot of awkward apologies.

Cost and cadence

The sequencer itself is included on all paid Origami plans. You only pay for the credits used to enrich leads. So once you’ve built a list, running the outreach campaign doesn’t cost extra. The only variable is how many new leads you enrich for future sequences. The free plan gives you 1,000 credits — enough to run a complete campaign on a small list and see how the system works.

What response rates to expect

For Series A healthtech founders, I’ve consistently seen:

• Connection acceptance rate: 22–28% if the note references their company’s specific stage or a known trigger (raise date, new hire, funding announcement)
• Positive reply rate (meeting booked or genuine interest): 7–12% from accepted connections, which translates to 1–2 meetings per 25 high-quality invites

These numbers assume you’re using the segmented sequences above and inviting people who genuinely match the persona. If you spray the same generic message to CTOs, clinical leads, and operations managers, acceptance drops to single digits — and reply quality plummets.

When to iterate on messaging vs. iterate on the list

If your connection acceptance rate falls below 15%, fix the note — probably it’s too vague about the healthtech context. If acceptance is high but reply rate is under 4%, your follow-up messages aren’t proving you understand the prospect’s specific load-bearing wall. Adjust the angle in touch 2, or swap in a stronger piece of “no-pitch” proof (a specific outcome for a similarly staged company).

If both numbers are solid but you’re struggling to convert replies into calls, the problem is not the sequence — it’s your qualification or your list. Go back to Step 2 and check whether you’re targeting people who actually own the problem you solve.

The entire loop — list, segment, sequence, send, track, refine — lives inside Origami. That’s the practical advantage: you don’t have to log into three different tools to figure out why a campaign is underperforming.